Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 9/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31633449 | 1.00 | DHODH (0.56) | DHODHMAPTMEN1KMT2ACHRNA7 | |
| SCHEMBL30210844 | 0.97 | DHODH (0.53) | DHODHMAPTMEN1KMT2ACHRNA7 | |
| SCHEMBL23930542 | 0.91 | KDM4E (0.59) | DHODHMAPTMEN1KMT2ACHRNA7 | |
| SCHEMBL30210871 | 0.88 | LMNA (0.55) | DHODHMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4486366 | 0.87 | MEN1 (0.60) | DHODHMAPTMEN1KMT2AKDM4E | |
| SCHEMBL31633457 | 0.86 | CCNA2 (0.50) | MAPTMEN1KMT2ACHRNA7LMNA | |
| SCHEMBL23930611 | 0.86 | CCNA2 (0.50) | MAPTMEN1KMT2ACHRNA7LMNA | |
| SCHEMBL3819003 | 0.85 | RAB9A (0.57) | DHODHMAPTMEN1KMT2ACHRNA7 | |
| SCHEMBL30210901 | 0.85 | KDM4E (0.55) | DHODHMAPTMEN1KMT2AKDM4E | |
| SCHEMBL4478262 | 0.84 | MAPT (0.54) | DHODHMAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4139287-B1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AG (DE) | 2025-02-26 | — | — | EP | disclosed |
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| EP-4139287-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2023-03-01 | — | — | EP | disclosed |
| CN-115697979-A | Substituted aminothiazoles as DGKZETA inhibitors for immune activation | 拜耳公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2021214020-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167103-A1 | SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION | DGKZ, DGKA, DGKG | DHODH 665/4885MAPT 3251/4885MEN1 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.